AKESO (09926) grants Hubei Jumpcan Pharmaceutical exclusive commercial rights to Ixen.

AKESO (09926) announced that its indirect wholly-owned subsidiary, Zhongshan AKESO Pharmaceuticals Limited and Kangrong Dongfang (Guangdong) Pharmaceuticals Limited (collectively referred to as "AKESO"), signed an Exclusive Commercialization Rights Agreement with Hubei Jumpcan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Hubei Jumpcan Pharmaceutical Group Co., Ltd. and Jiangsu Jiyuan Pharmaceuticals Co., Ltd. (collectively referred to as "Hubei Jumpcan Pharmaceutical") recently. Under this agreement, AKESO granted Hubei Jumpcan Pharmaceutical exclusive commercialization rights to the independently developed and approved for market listing drug, Yixining (Incliximab Injection), in the territory of the People's Republic of China (excluding Hong Kong, Macau, and Taiwan) during the collaboration period. In this collaboration, AKESO will receive a license fee of RMB 80 million (including tax) paid by Hubei Jumpcan Pharmaceutical, as well as milestone payments not exceeding RMB 10 million (including tax); Hubei Jumpcan Pharmaceutical will be responsible for the commercial promotion and sales of Yixining in the authorized market. Yixining (Incliximab Injection) is an innovative PCSK9 monoclonal antibody independently developed by the company, which was approved for market listing in September 2024 for the treatment of primary hypercholesterolemia and mixed hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia with atherosclerotic cardiovascular disease. Currently, Yixining has been included in the latest version of the National Medical Insurance Catalog and is highly recommended in the latest edition of the Management of Blood Lipids Related Cardiovascular Risk in China Expert Consensus (2025) and the Guidelines for Rational Use of Blood Lipid Anomalies and Comprehensive Management in Counties (2025). Yixining works by specifically binding to PCSK9 and blocking its interaction with LDL-R, restoring the expression level of LDL-R to enhance the clearance ability of LDL-C in plasma. Previous studies have shown that receiving PCSK9 antibody treatment on top of statin therapy can significantly reduce cholesterol levels in the body, lowering the risk of heart attacks and strokes for patients. Phase III clinical studies have demonstrated excellent clinical efficacy of Yixining for patients categorized as ultra-high risk, very high risk, high risk, and moderate to low risk, as well as patients regardless of their LDL-C levels, providing a new choice for the clinical treatment of hypercholesterolemia and long-term control of cardiovascular risk.